Personalized cancer vaccine clinical trial to expand following promising early results

(University of Arizona Health Sciences) A University of Arizona Health Sciences clinical trial to study safety and effectiveness of a personalized cancer vaccine combined with immunotherapy drug Pembrolizumab will expand after promising preliminary data was presented at the Society for the Immunotherapy of Cancer's annual meeting. Researcher Julie E. Bauman, MD, MPH, reported data on the first 10 patients with head and neck cancer, seven of whom were treated at Banner - University Medicine, clinical partner for the UArizona Cancer Center.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news